Integrative Care Approaches for Cardiorenal Syndrome

Explore the importance of integrative care for cardiorenal syndrome to optimize health outcomes and improve patient management.

Abstract: What This Post Covers

The relationship between the heart and the kidneys is among the most physiologically intricate and clinically challenging in modern medicine. When one organ falters, the other almost inevitably follows — a condition formally classified as cardiorenal syndrome (CRS). In this comprehensive educational post, I, Dr. Alex Jimenez, will guide you through the full spectrum of this condition: from the foundational hormonal tug-of-war between the heart’s natriuretic peptides and the kidneys’ renin-angiotensin-aldosterone system (RAAS), to the evolving hemodynamic understanding of venous congestion, the veno-renal state, and how elevated venous pressure silently destroys kidney function. We will walk through the essential diagnostic workup — laboratory panels, imaging, and physical assessment — before exploring the full landscape of evidence-based treatments, including diuretic pharmacology, guideline-directed medical therapy (GDMT), inotropic support, and advanced interventions such as ultrafiltration and mechanical circulatory support. Throughout this journey, I will share how our integrative model at Injury Medical Clinic PA — anchored by the medical oversight of Dr. Maria Guadalupe Cardenas, MD, and complemented by chiropractic care and functional medicine — creates a uniquely comprehensive framework for managing these complex, multisystem conditions.

Our Integrative Practice: Where Chiropractic Care Meets Internal Medicine

Before diving into the science, I want to introduce you to the collaborative foundation that makes our approach possible. At Injury Medical Clinic PA — also known as Mission Plaza Injury Medical Clinic — in El Paso, Texas, we have built a multidisciplinary practice that bridges traditional medical care and integrative health sciences.

I hold training and board certifications across multiple disciplines: Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), Family Nurse Practitioner-Board Certified (FNP-BC), Certified Functional Medicine Practitioner (CFMP), IFM Certified Practitioner (IFMCP), Athletic Trainer Certified (ATN), and Certified Chiropractic Sports Clinician (CCST). My clinical observations and perspectives are available at healthcoach. clinic and through my LinkedIn profile. This breadth of training allows me to evaluate patients not just structurally or biomechanically, but metabolically, neurologically, and functionally — as whole, interconnected systems.

Working alongside me is our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (NPI #1164426749, Texas MD License #J2933). Dr. Cardenas is Board Certified in Internal Medicine and brings over 40 years of experience as an internist to our team. She provides essential medical oversight — including diagnostic confirmation, prescription management, and the direction of complex medical care — ensuring that every patient receives treatment grounded in the highest standards of evidence-based internal medicine.

This multidisciplinary structure is common in modern integrative and injury care clinics, and it is precisely what allows us to offer something that neither a purely chiropractic nor a purely medical practice could offer alone. Our team integrates:

• Medical oversight from Dr. Cardenas (Internal Medicine)
• Chiropractic care and functional medicine from Dr. Jimenez
• Personal injury care and rehabilitation
• Nutritional and metabolic support
• Advanced diagnostic evaluation

Together, we treat the whole person — not just a diagnosis.

The Heart-Kidney Connection: Understanding the Biological Crosstalk

As of June 11, 2026, our clinical understanding of the heart-kidney relationship continues to deepen in meaningful ways. What was once viewed as two separate organ systems has been reframed by leading researchers as a continuous, bidirectional communication network — a “crosstalk” — in which each organ exerts direct influence on the other’s function and survival (Rangaswami et al., 2019).

The clearest manifestation of this relationship is cardiorenal syndrome, a condition in which dysfunction of one organ accelerates the deterioration of the other. When a patient presents with acute decompensated heart failure, it is extraordinarily common to find acute kidney injury (AKI) simultaneously. This is not coincidence — it is physiology.

The Endocrine Heart vs. The Endocrine Kidney: A Hormonal Tug-of-War

Most people recognize the kidneys as endocrine organs. Less commonly appreciated is that the heart is also an endocrine organ. When the ventricular walls are stretched by excess fluid volume, the heart releases a family of natriuretic peptides:

• Atrial Natriuretic Peptide (ANP)
• B-type Natriuretic Peptide (BNP)
• C-type Natriuretic Peptide (CNP)

These peptides act as a counterbalance against volume overload. They promote vasodilation (widening of the blood vessels), natriuresis (excretion of sodium in the urine), and subsequent fluid loss — all mechanisms designed to reduce blood pressure and unload the circulatory system.

On the opposing side stands the kidney’s Renin-Angiotensin-Aldosterone System (RAAS):

• Renin and Angiotensin II cause potent vasoconstriction to preserve blood pressure.
• Aldosterone signals the kidneys to retain sodium and water, expanding blood volume.

In health, these two systems maintain a careful equilibrium. In heart failure, that balance collapses. A useful analogy: when we observe an elevated BNP or NT-proBNP, it is tempting to think “the heart is stretched simply.” But a more precise interpretation is that this is an endocrine response — similar to how a rising TSH level in hypothyroidism signals that the pituitary is desperately trying to stimulate an underperforming thyroid. The heart is flooding the circulation with natriuretic peptides to counteract a dominant RAAS. And here is the critical point: the kidney is the stronger endocrine organ. Over time, the RAAS will overpower the natriuretic peptide system. The heart is engaged in an unfair fight it cannot win without help (Ronco et al., 2010).

The Pathophysiological Cascade: How Heart Failure Destroys Kidneys

Understanding why cardiorenal syndrome develops requires tracing the precise pathophysiological sequence that unfolds when the heart begins to fail.

Decreased Cardiac Output and Increased Preload

Heart failure, regardless of its initial cause, produces two immediate and destabilizing consequences:

1. Decreased cardiac output — the heart’s pumping efficiency declines, driven by reductions in stroke volume and increases in left ventricular wall stress.
2. Increased preload — as the heart weakens, pressure backs up through the cardiac chambers, elevating left atrial pressure and central venous pressure (CVP).

The body recognizes these events as a threat — evolutionarily interpreted as hemorrhagic blood loss — triggering two major compensatory systems.

RAAS Activation and Sympathetic Nervous System Overdrive

The kidneys respond to a fall in cardiac output by activating the RAAS, thereby driving vasoconstriction and sodium retention to “refill the tank.” Simultaneously, the sympathetic nervous system (SNS) is activated to increase heart rate and maintain cardiac output (since Cardiac Output = Heart Rate × Stroke Volume). The SNS also initiates a systemic inflammatory response, releasing pro-inflammatory cytokines throughout the body.

In the short term, these are brilliant survival mechanisms. In the chronic context of heart failure, they become profoundly destructive. The persistent activation of the RAAS and SNS drives:

• Glomerular and interstitial damage from cytokine-mediated inflammation, leading to sclerosis and fibrosis of nephron structures
• Worsening afterload on the heart, perpetuating the cycle of cardiac dysfunction
• Chronic fluid retention, manifest as pulmonary congestion, peripheral edema, and ascites

Oxidative Stress, Tubular Injury, and Vacuolization

Beyond the primary hormonal battle, the overactivated SNS generates excess reactive oxygen species (ROS), leading to widespread oxidative stress. In the kidneys, this damages the renal tubular cells, triggering apoptosis (programmed cell death). As the immune system clears these dead cells, they are replaced by non-functional scar tissue — fibrosis — that progressively erodes kidney capacity. Critically, this tubular injury independently activates the kidney’s own RAAS, meaning the system is now being driven from two directions simultaneously.

A particularly compelling phenomenon also occurs in the distal tubules: vacuolization—the formation of empty pockets within tubular cells. These vacuoles consume intracellular space, drastically reducing the effective surface area available for water and solute reabsorption. The result is a kidney that is structurally impaired in its most basic function: producing urine.

Abdominal Congestion: The Hidden Driver of Renal Dysfunction

When most clinicians think of fluid overload in heart failure, they picture swollen ankles. In reality, the peripheral extremities are the last place the body stores excess fluid. Long before the ankles swell, fluid saturates the splanchnic venous reservoir — the compliant venous network of the liver, spleen, omentum, and intestinal walls (Mullens et al., 2009).

As CVP rises, this abdominal reservoir becomes engorged. The consequences are profound:

• Increased intra-abdominal pressure compresses the renal veins, impairing venous outflow from the kidneys
• Gut edema causes malabsorption of nutrients and medications and allows bacterial toxins to enter the systemic circulation — fueling further inflammation.
• Hepatic congestion impairs metabolic and fluid balance throughout the body

On imaging, these patients often show abdominal wall edema, splenomegaly, and an inferior vena cava (IVC) that fails to collapse with inspiration — a key echocardiographic sign of elevated central venous pressure.

From Forward Flow to Backward Flow: The Evolution of Our Understanding

Our current understanding of cardiorenal syndrome was not built overnight. It evolved over four decades through pivotal advances in cardiac transplantation and hemodynamic monitoring.

The Age of Contractility

Early dogma held that contractility — the heart muscle’s intrinsic strength of contraction — was the paramount variable. High filling pressures were accepted as a necessary trade-off to sustain cardiac output. The solution seemed simple: make the heart squeeze harder.

The Hemodynamic Revolution

The widespread adoption of pulmonary artery (PA) catheters in heart transplant patients produced an avalanche of hemodynamic data. Clinicians began mapping patients by their hemodynamic profiles, recognizing the critical role of systemic vascular resistance (SVR). Reducing SVR with vasodilators became a cornerstone strategy — improving forward flow by reducing the mechanical resistance the heart had to overcome.

The Right Ventricle Steps Forward

More recently, research has shifted attention to the right ventricle (RV) — long dismissed as a passive conduit between systemic veins and the pulmonary circulation. We now understand that the RV is our priming pump. It determines the preload delivered to the left ventricle, and critically, RV dysfunction is the primary driver of the venous hypertension that propagates throughout the body in heart failure.

Introducing the Veno-Renal State

This realization culminated in a paradigm-shifting concept: the veno-renal state. Kidney function depends on a pressure gradient across the glomerulus — high arterial inflow pressure versus low venous outflow pressure. When venous pressure rises due to heart failure, the outflow pressure from the kidney increases, narrowing the filtration gradient, slowing glomerular filtration rate (GFR), and causing GFR to plummet.

The implication is transformative: adequate forward arterial flow to the kidneys is necessary but not sufficient. It is equally essential to decongest the venous outflow by maintaining low renal vein pressure. Managing venous hypertension is now recognized as important as improving cardiac output (Mullens et al., 2009).

Diagnosing Cardiorenal Syndrome: A Systematic Clinical Approach

When a patient presents with dyspnea and suspected cardiorenal dysfunction, the first imperative is to cast a wide diagnostic net — because these patients rarely have a single, simple problem.

Essential Laboratory Workup

Test	Clinical Rationale
Complete Blood Count (CBC)	Rules out infection (elevated WBC) and severe anemia (low hemoglobin), both of which can mimic or worsen heart failure symptoms
Comprehensive Metabolic Panel (CMP)	Preferred over BMP because it includes liver function tests — the liver and kidneys are “ride or die” friends that often fail together under systemic congestion
BNP or NT-proBNP	Direct biomarker of ventricular stretch and cardiac stress; elevated levels confirm hemodynamic overload
Lactate	A critically underutilized marker of tissue malperfusion; helps risk-stratify patients beyond simple congestion.
Troponin	Identifies acute myocardial injury or extreme myocardial strain driving the current decompensation
Urinalysis and Urine Microalbumin	Detects proteinuria signaling chronic kidney damage; rules out nephrotic syndrome, which can masquerade as heart failure.

One point I emphasize repeatedly in practice: a single creatinine value is meaningless without context. When I receive a call about a patient with a creatinine of 1.9 mg/dL, I immediately examine the longitudinal chart. If prior values were 1.7 and 1.8 mg/dL, that 1.9 may be their baseline. The distinction between a true AKI, AKI superimposed on CKD, or a stable elevated baseline dictates an entirely different clinical response.

For this reason, I monitor glomerular filtration rate (GFR) more carefully than creatinine alone. GFR gives us a functional picture of kidney capacity and guides medication decisions:

• GFR > 30: Safe threshold for initiating ARNIs, ACE inhibitors, ARBs, and MRAs
• GFR > 20: Threshold for initiating SGLT2 inhibitors, which carry both cardiac and renal protective benefits

CKD staging by GFR:

• Stage 1: GFR > 90 (Normal)
• Stage 2: GFR 60-89 (Mildly decreased)
• Stage 3: GFR 30-59 (Mild to moderately decreased)
• Stage 4: GFR 15-29 (Severely decreased)
• Stage 5: GFR < 15 (Kidney failure — dialysis consideration begins)

Key Imaging and Diagnostic Studies

• Echocardiogram: Evaluates cardiac structure, ejection fraction (EF), valvular function, and RV performance. I order a new echo if the patient has not had one within the past six months.
• Renal Ultrasound: Rules out post-obstructive causes of AKI, such as hydronephrosis. I have personally encountered a diabetic patient with neurogenic bladder whose bladder retained nearly six liters of urine — decompression alone dramatically restored kidney function.
• 12-Lead EKG: Identifies ischemia, acute myocardial infarction, and arrhythmias such as atrial fibrillation, which can be a powerful independent trigger for acute decompensated heart failure.

Physical Assessment: Reading the Body’s Signals

Laboratory data and imaging are only part of the picture. A thorough physical assessment reveals the hemodynamic story in real time.

NYHA Functional Classification

The New York Heart Association (NYHA) functional classification is the standard framework for assessing heart failure severity based on symptom burden:

• Class I: No limitation of physical activity
• Class II: Slight limitation; ordinary activity produces symptoms — a reasonable management target for many chronic heart failure patients
• Class III: Marked limitation; less than ordinary exertion causes symptoms — this patient may stop to catch their breath crossing a parking lot
• Class IV: Symptoms at rest — this patient may be breathless walking from the bed to the bathroom and often requires a shower chair

Distinguishing Congestion from Malperfusion

Signs of Congestion:

• Orthopnea: Shortness of breath lying flat — I ask “Can you comfortably lie flat?” and “How many pillows do you sleep on?” rather than a yes-or-no question
• Paroxysmal Nocturnal Dyspnea (PND): Sudden awakening with breathlessness, often described by patients as a nighttime panic attack — I have seen patients prescribed anxiolytics for what was unrecognized PND
• Bendopnea: Shortness of breath when bending forward, such as tying a shoe — a highly specific sign that can be directly observed in the exam room
• Dyspnea on exertion (DOE): Assessed with concrete functional questions: “Can you push a vacuum? Can you walk through a Walmart parking lot without stopping?”
• Weight gain, early satiety, abdominal bloating, and peripheral edema

Signs of Malperfusion:

• Profound fatigue and intermittent confusion (reduced cerebral perfusion)
• Oliguria (reduced urine output)
• Elevated lactate and worsening laboratory organ function markers

The Four Hemodynamic Profiles

Profile	Perfusion	Fluid Status	Clinical Significance
Warm and Wet	Adequate	Congested	Most common presentation; primary target for diuresis
Cold and Wet	Poor	Congested	High-risk; requires aggressive combined intervention
Warm and Dry	Adequate	Euvolemic	The treatment goal
Cold and Dry	Poor	Euvolemic	May need volume or inotropic support

The Five Phenotypes of Cardiorenal Syndrome

Cardiorenal syndrome is not a single disease — it is a family of related conditions classified into five distinct types (Ronco et al., 2010):

• Type 1 (Acute Cardiorenal Syndrome): Acute heart failure causes acute kidney injury — the most common inpatient presentation
• Type 2 (Chronic Cardiorenal Syndrome): Chronic heart failure drives progressive CKD
• Type 3 (Acute Renocardiac Syndrome): Acute kidney injury (e.g., glomerulonephritis) precipitates acute cardiac dysfunction
• Type 4 (Chronic Renocardiac Syndrome): CKD causes ventricular hypertrophy and diastolic heart failure
• Type 5 (Secondary Cardiorenal Syndrome): A systemic disease — such as lupus, vasculitis, or sepsis — damages both organs simultaneously

Diuretic Therapy: The Cornerstone of Decongestion

Managing fluid overload in cardiorenal syndrome begins with diuretic therapy — the most immediate and impactful tool available. By promoting sodium and fluid excretion, diuretics:

• Reduce systemic and pulmonary congestion
• Lower cardiac filling pressures and LV wall stress
• Relieve pressure on end-organs, including the kidneys and liver

However, every diuretic dose comes with a trade-off: activation of the RAAS. As the body senses fluid loss, it responds by increasing renin and aldosterone secretion, thereby driving compensatory sodium retention. This neurohormonal braking effect is why diuretic therapy must be thoughtfully dosed, timed, and combined.

Navigating the Nephron: Where Each Diuretic Acts

The nephron — the functional unit of the kidney — processes filtrate through several anatomical segments, each targetable by different drug classes:

• Proximal Convoluted Tubule: SGLT2 inhibitors (empagliflozin, dapagliflozin) and carbonic anhydrase inhibitors (acetazolamide) inhibit glucose and sodium reabsorption
• Ascending Loop of Henle: Loop diuretics (furosemide, torsemide, bumetanide) block the Na-K-2Cl symporter, producing the most powerful diuresis available
• Distal Convoluted Tubule: Thiazide diuretics (hydrochlorothiazide, metolazone) block the Na-Cl cotransporter for a more modest but synergistic effect
• Collecting Duct: Mineralocorticoid receptor antagonists (MRAs) — spironolactone, eplerenone — block aldosterone, promoting sodium excretion while conserving potassium

When a single agent is insufficient, sequential nephron blockade — using agents targeting different nephron segments simultaneously — produces a powerful synergistic diuretic effect.

Threshold and Ceiling: The Pharmacological Framework

Every diuretic has two critical dosing parameters:

• Threshold: The minimum concentration required to produce a therapeutic response. This threshold rises significantly with renal impairment, significant edema, and extracellular fluid expansion. In patients with CRS and an elevated creatinine, the threshold can be dramatically higher than expected — a dose that works in one patient may produce no response whatsoever in another.
• Ceiling: The maximum dose at which the drug’s effect plateaus. Beyond this ceiling, increasing the dose yields no additional fluid removal — only an increased risk of side effects, including electrolyte disturbances and ototoxicity.

Recognizing the ceiling is a pivotal clinical skill. When a patient reaches their ceiling dose without adequate diuresis, the correct response is not to increase that dose further — it is to add a second agent from a different nephron segment or escalate to advanced therapies.

Comparing the Loop Diuretics: Furosemide, Torsemide, and Bumetanide

Diuretic	Oral Potency Equivalence	IV Conversion	Oral Bioavailability	Max Daily Dose
Furosemide (Lasix)	40 mg	2:1 (oral: IV)	10-100% (highly variable)	600 mg
Torsemide (Demadex)	20 mg	1:1	80-100%	200 mg
Bumetanide (Bumex)	1 mg	1:1	80-100%	10 mg

The most consequential difference among these agents is oral bioavailability. Furosemide’s absorption can range from 10% to 100% — a staggering variability largely driven by gut edema in patients with heart failure. A patient absorbing only 10% of their furosemide dose is, in practice, receiving almost no diuresis. In my clinical practice, I have moved away from oral furosemide almost entirely, instead favoring torsemide and bumetanide for outpatient therapy due to their reliable 80-100% bioavailability and predictable pharmacokinetics.

Potency equivalence is another critical area of error. A patient stable at home on 40 mg of torsemide is receiving the equivalent of 80 mg of furosemide. If that patient is admitted to the hospital and switched to 40 mg of furosemide without dose adjustment, their diuretic dose has effectively been halved. This mistake alone can cause or worsen in-hospital decompensation.

Dosing Timing: Why Scheduling Matters

Loop diuretics vary in their duration of action. Bumetanide has the shortest half-life, furosemide is intermediate, and torsemide has the longest. A single morning dose of a short-acting loop diuretic may produce brisk diuresis but allow post-diuretic sodium retention (compensatory reabsorption) to occur throughout the afternoon and evening. For this reason, I typically prescribe loop diuretics twice daily.

In the hospital setting, timing matters enormously for patient safety. A diuretic dose at 9 PM will send a patient to the bathroom repeatedly through the night, increasing the risk of falls and sleep deprivation. My preferred inpatient schedule is 6-7 AM and 4-5 PM, ensuring the evening dose’s peak effect resolves before bedtime. For outpatients, I recommend the first dose upon waking and the second dose approximately one hour after lunch.

IV Push vs. Continuous Infusion: Evidence from the DOSE Trial

The DOSE (Diuretic Optimization Strategies Evaluation) trial (Felker et al., 2011) demonstrated that for most patients with acute decompensated heart failure, intermittent IV boluses are as effective as continuous infusion, provided the correct dose is administered. However, in patients with severe diuretic resistance, a continuous infusion maintains a steady nephron concentration of the drug, helping overcome the neurohormonal braking phenomenon. For my most challenging, fluid-refractory patients, I use a continuous diuretic drip as a preferred strategy.

Advanced Diuretic Management Principles

Several principles guide diuretic use in the context of CRS:

1. Do not underdose: Patients with CRS have a dramatically elevated diuretic threshold. A patient with a creatinine of 3.0 mg/dL and anasarca will not respond to 20 mg of IV furosemide. Meaningful doses may be 80, 120, or even higher.
2. Expect a transient rise in creatinine: A modest increase of up to 0.5 mg/dL after initiating diuresis is common and expected — it reflects RAAS activation and intravascular volume contraction, not true structural AKI. Prematurely stopping diuretics or administering IV fluids in response to this rise is a significant and common error.
3. Recognize and respond to diuretic resistance: If fluid balance goals are not met despite escalating loop diuretic doses, add metolazone (a thiazide) 30 minutes before the loop diuretic to achieve sequential nephron blockade.
4. Escalate appropriately: Persistent diuretic resistance despite combination therapy warrants nephrology and heart failure specialist involvement, and consideration of ultrafiltration or inotropic support.

Beating the Odds: “Conquering Congestive Heart Failure”- Video

Guideline-Directed Medical Therapy: Treating the Disease, Not Just the Symptoms

Diuretics manage congestion — they do not reverse heart failure. Improving underlying cardiac function requires Guideline-Directed Medical Therapy (GDMT), which should be initiated and optimized as early as safely possible, even during acute hospitalization.

The Four Pillars of GDMT

• ARNIs (Sacubitril/Valsartan), ACE Inhibitors, or ARBs: Reduce RAAS activity, decrease afterload, and slow cardiac remodeling — initiate when eGFR > 30 mL/min/1.73m²
• Mineralocorticoid Receptor Antagonists (MRAs): Block aldosterone-mediated sodium retention and fibrosis — also safe above eGFR of 30, but requires vigilant potassium monitoring.
• SGLT2 Inhibitors (empagliflozin, dapagliflozin): Provide mild diuresis, reduce hospitalizations, and carry proven cardiorenal protective effects — can be initiated at eGFR > 20 mL/min/1.73m²
• Beta-Blockers: Critical for long-term cardiac remodeling, but must not be initiated in acutely decompensated, fluid-overloaded patients — their negative inotropic effect can worsen hemodynamics in the “cold and wet” state. The priority is decongestion first; beta-blocker initiation follows once the patient is approaching euvolemia.

Inotropic Support: When the Heart Cannot Help the Kidneys

In some patients with severe CRS, the heart’s function is so depressed that even aggressive diuresis fails to achieve adequate renal decongestion. These patients develop refractory oliguria — a state where the kidneys produce little to no urine despite high diuretic doses. In this setting, inotropic therapy is necessary to improve cardiac output and relieve venous congestion that is crushing kidney function.

• Dobutamine: Acts on beta-1 receptors to increase heart rate and contractility. Particularly valuable for RV support, as the RV is highly rate-dependent for its contractile efficiency. Improving RV function reduces CVP and relieves renal venous congestion.
• Milrinone: A phosphodiesterase-3 inhibitor that enhances cardiac contractility while simultaneously providing potent pulmonary vasodilation. By reducing pulmonary vascular resistance and RV afterload, milrinone allows the RV to empty more effectively, lowering CVP, reducing renal vein pressure, widening the glomerular pressure gradient, and restoring kidney perfusion.

Both agents require careful monitoring for tachyarrhythmias and increased myocardial oxygen demand. In my practice, I initiate these agents at a fixed, low dose and assess urine output over the subsequent 4-6 hours before any titration.

Advanced Interventions: When All Else Fails

Ultrafiltration

When pharmacological decongestion is inadequate, ultrafiltration — mechanical fluid removal through a filter membrane — can bypass the neurohormonal braking mechanisms entirely. Unlike diuretics, ultrafiltration removes fluid and electrolytes without activating the RAAS. It can be delivered as continuous renal replacement therapy (CRRT) — preferred in hemodynamically unstable patients for its gentle, continuous nature — or as intermittent hemodialysis. Remarkably, as mechanical decompression relieves venous pressure on the kidneys, many patients begin producing their own urine again, with native kidney function recovering in parallel.

Mechanical Circulatory Support

In cases of profound cardiogenic shock driving severe CRS, mechanical circulatory support (MCS) may be required:

• Impella: A catheter-based cardiac assist device capable of unloading either the left ventricle (LV) or right ventricle (RV). LV unloading reduces filling pressures, secondarily improving RV function and relieving systemic venous congestion — and with it, renal congestion.
• ECMO (Extracorporeal Membrane Oxygenation): Provides complete biventricular and respiratory support for the most critically ill patients who have exhausted all other therapeutic options.

These are highly specialized, resource-intensive interventions reserved for patients in refractory cardiogenic shock.

Integrative Chiropractic and Functional Medicine Support in Cardiorenal Syndrome

At Injury Medical Clinic PA, we believe that managing cardiorenal syndrome requires more than pharmacology — it requires addressing the patient’s full biological terrain. While Dr. Cardenas directs the medical and pharmacological management, my role focuses on the systemic, neurological, and metabolic dimensions of health.

Modulating the Autonomic Nervous System

One of the central pathological drivers in CRS is chronic sympathetic nervous system overdrive — a relentless activation of the “fight or flight” response that floods the body with inflammatory cytokines and perpetuates RAAS activation. The autonomic nervous system is intimately connected to the spinal column through the thoracic sympathetic chain. Dysfunctions in spinal mechanics can create neurological interference that sustains or amplifies this sympathetic overdrive.

Through specific chiropractic adjustments, I aim to restore proper spinal biomechanics and reduce neurological interference, supporting a shift toward parasympathetic (rest-and-digest) dominance. While chiropractic care does not directly treat heart failure, supporting healthy autonomic balance may contribute to improved heart rate variability, more normalized blood pressure regulation, and reduced systemic stress burden — all of which support better cardiovascular and renal outcomes.

Combating Inflammation and Oxidative Stress

From a functional medicine perspective, the inflammatory and oxidative dimensions of CRS are areas where nutritional and metabolic interventions can provide meaningful support. I use advanced diagnostic testing to assess:

• Nutritional status and micronutrient deficiencies
• Gut microbiome health (gut edema in CRS directly impairs barrier integrity and drives systemic inflammation)
• Mitochondrial function (both the heart and kidneys are extraordinarily energy-demanding organs, densely packed with mitochondria that are vulnerable to ROS-mediated damage)

Targeted interventions include:

• Anti-inflammatory nutrition: Diets rich in omega-3 fatty acids, polyphenols, and antioxidants to reduce the cytokine burden
• Mitochondrial support: Coenzyme Q10 (CoQ10), L-carnitine, and D-ribose to restore cellular energy production in damaged cardiomyocytes and tubular cells
• Antioxidant supplementation: Curcumin, fish oil, and N-acetylcysteine (NAC) to combat oxidative stress and support cellular integrity

Addressing Mechanical and Mobility Factors

Venous congestion and systemic edema cause significant musculoskeletal discomfort, joint stiffness, and impaired mobility. Our rehabilitation team works with these patients to:

• Guide diaphragmatic breathing exercises that improve fluid dynamics and reduce intra-abdominal pressure
• Provide gentle core stabilization work to support abdominal decompression and improve circulatory efficiency
• Offer soft tissue therapies to improve lymphatic drainage, reduce musculoskeletal tension from fluid retention, and enhance overall comfort and functional capacity.y

These interventions do not cure cardiorenal syndrome — but they profoundly improve thepatient’ss quality of life and resilience. At the same time, they undergo the complex medical treatments necessary to address the underlying condition.

Conclusion: A Unified Path Forward for Heart and Kidney Health

Cardiorenal syndrome is one of the most complex and consequential conditions encountered in modern clinical practice. It demands an understanding that extends from molecular endocrinology — the tug-of-war between natriuretic peptides and the RAAS — to macroscopic hemodynamics, from the subtle signs of bendopnea in the exam room to the nuanced pharmacokinetics of loop diuretics. It requires recognizing that venous congestion, not just reduced forward flow, is a primary driver of kidney injury; that the right ventricle has been the forgotten engine of systemic fluid dynamics; and that the most advanced interventions — ultrafiltration, mechanical circulatory support — exist precisely because this condition can overwhelm even our most aggressive pharmacological tools.

At Injury Medical Clinic PA, the collaboration between my integrative, functional, and chiropractic practice and the exceptional internal medicine expertise of Dr. Maria Guadalupe Cardenas, MD allows us to approach these patients with a comprehensive framework. We do not simply manage a diagnosis. We evaluate the whole person — their autonomic nervous system, inflammatory burden, metabolic health, and structural and biomechanical function — and build a treatment plan that addresses every dimension of their condition.

The science of cardiorenal syndrome continues to evolve, and I am committed to bringing the latest evidence-based insights to my patients and our community. If you or someone you know is managing heart failure, kidney disease, or both, I encourage you to explore what an integrative approach can offer.

References

Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., … O’Connor, C. M. (2011). Diuretic strategies in patients with acute decompensated heart failure. New England Journal of Medicine, 364(9), 797-805. doi.org/10.1056/NEJMoa1005419

House, A. A., Wanner, C., Sarnak, M. J., Piña, I. L., McIntyre, C. W., Komenda, P., & Ronco, C. (2019). Heart failure in chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 77(2), 97-109. doi.org/10.1038/ki.2009.460

Mullens, W., Abrahams, Z., Francis, G. S., Sokos, G., Taylor, D. O., Starling, R. C., Young, J. B., & Tang, W. H. W. (2009). Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. Journal of the American College of Cardiology, 53(7), 589-596. doi.org/10.1016/j.jacc.2008.05.068

Rangaswami, J., Bhalla, V., Blair, J. E. A., Chang, T. I., Costa, S., Lentine, K. L., & Lerma, E. V. (2019). Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association. Circulation, 140(3), e56-e94. doi.org/10.1161/CIR.0000000000000694

Ronco, C., McCullough, P., Anker, S. D., Anand, I., Aspromonte, N., Bagshaw, S. M., & Berl, T. (2010). Cardio-renal syndromes: Report from the consensus conference of the Acute Dialysis Quality Initiative. European Heart Journal, 31(6), 703-711. doi.org/10.1093/eurheartj/ehp507

Stevenson, L. W. (1999). The management of advanced heart failure. Heart, 82(Suppl 4), IV23-IV28. doi.org/10.1136/hrt.82.2008.iv23

SEO Tags: Cardiorenal Syndrome, Heart Failure and Kidney Disease, Cardiorenal Syndrome Treatment, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, Injury Medical Clinic PA, El Paso TX, Integrative Chiropractic Care, Functional Medicine, Right Ventricle Dysfunction, Venous Congestion, Veno-Renal State, RAAS Activation, Natriuretic Peptides, BNP NT-proBNP, Diuretic Therapy, Furosemide vs Torsemide, Sequential Nephron Blockade, DOSE Trial, Guideline-Directed Medical Therapy, SGLT2 Inhibitors Heart Failure, Inotropic Support, Dobutamine Milrinone, Ultrafiltration Heart Failure, Mechanical Circulatory Support, Impella ECMO, GFR Chronic Kidney Disease, Acute Kidney Injury Heart Failure, NYHA Classification, Orthopnea Bendopnea, Hemodynamic Profiles Heart Failure, Abdominal Congestion Heart Failure, Oxidative Stress Cardiorenal, Autonomic Nervous System Chiropractic, Mitochondrial Support Heart Failure, Integrative Medicine El Paso, Multidisciplinary Cardiology Care